Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0DV3T
|
|||
| Former ID |
DIB006387
|
|||
| Drug Name |
Epoetin zeta
|
|||
| Indication | Anemia [ICD-11: 3A00-3A9Z; ICD-9: 280-285] | Phase 3 | [1] | |
| Company |
Hospira
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Erythropoietin Receptor (EPOR) | Target Info | Modulator | [2] |
| KEGG Pathway | Cytokine-cytokine receptor interaction | |||
| PI3K-Akt signaling pathway | ||||
| Jak-STAT signaling pathway | ||||
| Hematopoietic cell lineage | ||||
| NetPath Pathway | TGF_beta_Receptor Signaling Pathway | |||
| Pathway Interaction Database | Signaling events mediated by Stem cell factor receptor (c-Kit) | |||
| EPO signaling pathway | ||||
| WikiPathways | EPO Receptor Signaling | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Comparison of the therapeutic effects of epoetin zeta to epoetin alfa in the maintenance phase of renal anaemia treatment. Curr Med Res Opin. 2008 Mar;24(3):625-37. | |||
| REF 2 | Long-term safety and tolerability of epoetin zeta, administered intravenously, for maintenance treatment of renal anemia. Adv Ther. 2008 Nov;25(11):1215-28. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.